Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 4—April 2025
Research

Carbapenem-Resistant, Virulence Plasmid–Harboring Klebsiella pneumoniae, United States

Jianping Jiang, Tengfei Long, Adeline R. Porter, Arianne Lovey, Annie Lee, Jesse Thomas Jacob, Cesar A. Arias, Robert Bonomo, Robert Kalayjian, Yanan Zhao, Frank R. DeLeo, David van Duin, Barry N. KreiswirthComments to Author , and Liang ChenComments to Author 
Author affiliation: Hackensack-Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA (J. Jiang, T. Long, A. Lovey, A. Lee, Y. Zhao, B.N. Kreiswirth, L. Chen); National Institute of Allergy and Infectious Disease Rocky Mountain Laboratories, Hamilton, Montana, USA (A.R. Porter, F.R. DeLeo); Emory University, Atlanta, Georgia, USA (J.T. Jacob); Houston Methodist Hospital and Houston Methodist Research Institute, Houston, Texas, USA (C.A. Arias); Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA (R.A. Bonomo); Case Western Reserve University School of Medicine, Cleveland (R.A. Bonomo); MetroHealth Medical Center, Cleveland (R. Kalayjian); University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA (D. van Duin)

Main Article

Table 3

Antimicrobial resistance of isolates in study of carbapenem-resistant, virulence plasmid–harboring Klebsiella pneumoniae isolates, United States*

Drug Isolate
ARLG-4622 ARLG-3254 ARLG-4744 ARLG-7683 ARLG-3484 ARLG-4720
Aztreonam R R R R R R
Ceftriaxone R R R R R R
Ceftazidime R R R R R R
Cefiderocol S S S ND S S
Ertapenem R R R R R R
Imipenem R R S S R R
Meropenem R R S S R R
Ciprofloxacin R S R R R R
Levofloxacin R S R R R R
Fosfomycin S S R R S R
Trimethoprim/sulfamethoxazole S R R R R R
Colistin I I I I R R
Piperacillin/tazobactam R R R I R R
Meropenem/vaborbactam S S S S R R
Ceftazdimie/avibactam S S S S S S

*I, intermediate; ND, not determined; R, resistant; S, susceptible.

Main Article

Page created: February 18, 2025
Page updated: March 11, 2025
Page reviewed: March 11, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external